(PubMed) Babaknejad N, Sayehmiri F, Sayehmiri K, et al
Companies are racing to develop alternatives to injectable diabetes and weight loss drugs Injectable peptide drugs targeting the glucagon-like peptide 1 (GLP-1) receptor have had massive impact on approaches to treating diabetes and obesity, bringing huge revenue boosts to makers Novo Nordisk and Eli Lilly
Obesity, particularly central or abdominal obesity, increases insulin resistance, thereby making it difficult for the body to regulate blood sugar levels
Many patients combine peptide therapy with PRP/PRF treatments for hair restoration or skin rejuvenation, NAD+ therapy for cellular energy and longevity support, hormone optimization for comprehensive wellness, and microneedling with growth factors for skin healing
As these therapies become standard rather than exceptional, imaging must evolve from reacting to change to understanding it
By linking pharmacy claims, electronic medical records, social determinants and lab results, we can uncover patterns in adherence, dosing and comorbidities that clinical trials cant reveal